Carboplatin

产品说明书

Print
Chemical Structure| 41575-94-4 同义名 : NSC 241240; CBDCA; Ribocarbo; Platinwas; Paraplatine; JM-8
CAS号 : 41575-94-4
货号 : A305076
分子式 : C6H12N2O4Pt
纯度 : 99%
分子量 : 371.25
MDL号 : MFCD00070464
存储条件：

Pure form Keep in dark place,Inert atmosphere,2-8°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

H2O: 10 mg/mL(26.94 mM)，配合低频超声，并水浴加热至45℃助溶
生物活性
靶点

  • DNA synthesis
描述 Carboplatinum is the second generation platinum anticancer drug with nonspecific cell cycle and similar effect to alkylating agent. A decrease in carboplatinum hemotoxicity was detected in experiments on C57B1 mice treated with the drug in combination with indralin (urgent radioprotector). Carboplatinum in a dose of 125 mg/kg, injected intraperitoneally, caused 80-100% death; the median term of death was 6 days (3-17)[3]. S. typhimurium A1-R and CAR (Carboplatinum) moderately inhibited tumor growth compared to the untreated group on day 15 (P < 0.001 and P < 0.001, respectively). S. typhimurium A1-R combined with CAR inhibited the tumor growth significantly more compared to S. typhimurium A1-R monotherapy or CAR monotherapy on day 15 (P = 0.004 and P = 0.001, respectively)[4]. In vitro synergistic efficacy of MK-2206 when combined with carboplatinum and paclitaxel in the three cell lines examined. Efficacy was dose dependent[5]. Sequential therapy with carboplatin plus paclitaxel followed by topotecan, all given at standard doses, is feasible and provides favorable response rates[6].
细胞研究
细胞系 浓度 检测类型 检测时间 活性说明 数据源
3AO Growth Inhibition Assay 72 h IC50=63.4 μM 25520132
4T1 Growth Inhibition Assay IC50=84.62 ± 30.05 μM μM 25277461
A2780 Growth Inhibition Assay 72 h IC50=145.7 μM 25520132
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.69mL

0.54mL

0.27mL

13.47mL

2.69mL

1.35mL

26.94mL

5.39mL

2.69mL
参考文献

[1]Vasin MV, Ushakov IB, Kovtun VY, Komarova SN, Semenova LA. Effect of radioprotector indralin on carboplatinum hemotoxicity. Bull Exp Biol Med. 2006 Apr;141(4):437-9

[2]Miyake K, Kiyuna T, Miyake M, Zhao M, Wangsiricharoen S, Kawaguchi K, Zhang Z, Higuchi T, Razmjooei S, Li Y, Nelson SD, Russell T, Singh A, Murakami T, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Singh SR, Chawla SP, Eilber FC, Endo I, Hoffman RM. Tumor-targeting Salmonella typhimurium A1-R overcomes partial carboplatinum-resistance of a cancer of unknown primary (CUP). Tissue Cell. 2018 Oct;54:144-149

[3]Almhanna K, Cubitt CL, Zhang S, Kazim S, Husain K, Sullivan D, Sebti S, Malafa M. MK-2206, an Akt inhibitor, enhances carboplatinum/paclitaxel efficacy in gastric cancer cell lines. Cancer Biol Ther. 2013 Oct 1;14(10):932-6

[4]Bolis G, Scarfone G, Tateo S, Mangili G, Villa A, Parazzini F. Response and toxicity to topotecan in sensitive ovarian cancer cases with small residual disease after first-line treatment with carboplatinum and paclitaxel. Gynecol Oncol. 2001 Jan;80(1):13-5